查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1611207

肿瘤坏死因子（TNF）抑制剂的全球市场规模、份额和趋势分析报告：按产品、应用、销售管道、地区和细分市场预测（2025-2030）

Tumor Necrosis Factor Inhibitor Drugs Market Size, Share & Trends Analysis Report By Product (Humira, Enbrel Remicade, Simponi/Simponi Aria, Cimzia), By Application, By Sales Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

肿瘤坏死因子 (TNF) 抑制剂市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球肿瘤坏死因子（TNF）抑制剂市场规模将达到266亿美元，2025年至2030年复合年增长率为2.2%。

自体免疫疾病盛行率的增加、技术的快速进步以及全球医疗保健支出的增加是预计推动成长的一些关键因素。

目前市面上有五种核准的TNF 抑制剂： Humira（Adalimumab）、 Enbrel（Etanercept）、 Remicade（Infliximab）、Simponi/Simponi Aria（戈利木单抗）和Cimzia （赛妥珠单抗）。生物相似药Humira、 Enbrel和Remicade的推出为市场带来了重大模式转移。

生物相似药浪潮对生物製药的销售构成了重大的内部威胁，因为生物相似药的效率与原厂药相当。生物相似药具有成本效益，使其成为经济敏感地区的有吸引力的选择。此外，印度、中国、韩国等新兴国家也积极进入生物相似药市场。

涉及TNF抑制剂治疗的关键治疗领域包括类风湿性关节炎、干干癣、干癣干癣性关节炎、克隆氏症和溃疡性大肠炎。儘管这些药物主要用于治疗自体免疫疾病，但一些正在进行的研究正在调查 TNF 抑制剂在治疗癌症和其他发炎性疾病中的作用。

TNF抑制剂领域的一些主要公司参与了併购和合资企业联合产品开发等策略性措施。此外，厂商之间的专利侵权问题也加剧了市场竞争。例如，艾伯维 (AbbVie) 与勃林格殷格翰 (Boehringer Ingelheim) 解决了有关修美乐 (Humira ) 的智慧财产权 (IP) 问题。根据该协议，勃林格殷格翰获得了Humira在美国的智慧财产权非独家许可。

肿瘤坏死因子 (TNF) 抑制剂市场报告亮点

  • 从产品来看，Humira）在2024年以40.5%的最大销售份额占据市场主导地位，因为它已证明其对多种自体免疫疾病的有效性，并在患者和医疗保健专业人员中建立了牢固的信任。
  • 2024年，类风湿性关节炎因其在全球范围内的高盛行率而占据市场主导地位，占据最大的收益占有率，达到17.51%。
  • 由于易于存取数位平台、顺利订购、准时交货和实惠的价格，线上药局预计在预测期内将以最高的复合年增长率成长。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章肿瘤坏死因子 (TNF) 抑制剂市场变数、趋势和范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 肿瘤坏死因子（TNF）抑制剂市场分析工具
    • 波特的分析
    • PESTEL分析

第四章肿瘤坏死因子（TNF）抑制剂市场：产品估算与趋势分析

  • 产品市场占有率（2024/2030）
  • 产品细分仪表板
  • 按产品分類的市场规模、预测和趋势分析（2018-2030）
  • Humira
  • Enbrel
  • Remicade
  • Simponi/Simponi Aria
  • Cimzia
  • 生物相似药

第五章肿瘤坏死因子（TNF）抑制剂市场：应用预估及趋势分析

  • 应用市场占有率（2024/2030）
  • 使用细分仪表板
  • 按应用分類的市场规模、预测和趋势分析（2018-2030）
  • 类风湿性关节炎
  • 干癣
  • 干癣性关节炎
  • 克隆氏症
  • 溃疡性大肠炎
  • 溃疡性大肠炎：市场收益估计与预测（2018-2030）
  • 僵直性脊椎炎
  • 幼年特发性关节炎
  • 化脓性汗腺炎
  • 其他的

第六章肿瘤坏死因子（TNF）抑制剂市场：销售管道估算及趋势分析

  • 销售管道市场占有率（2024/2030）
  • 销售管道细分仪表板
  • 按销售管道分類的市场规模、预测和趋势分析（2018-2030）
  • 医院药房
  • 专业药房
  • 网路药房

第七章肿瘤坏死因子（TNF）抑制剂市场：区域估计和趋势分析

  • 区域市场占有率分析（2024/2030）
  • 区域市场仪表板
  • 市场规模及预测趋势分析（2018-2030）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国

第八章 竞争格局

  • 参与企业概况
  • 公司市场分析
  • 公司分类
  • 策略规划
  • 公司简介/上市公司
    • AbbVie, Inc.
    • Amgen, Inc.
    • Johnson &Johnson Services, Inc.
    • UCB SA
    • Pfizer, Inc.
    • Novartis International AG
    • Boehringer Ingelheim Pharmaceuticals, Inc.
    • Merck &Co., Inc.
Product Code: GVR-3-68038-150-4

Tumor Necrosis Factor Inhibitor Drugs Market Growth & Trends:

The global tumor necrosis factor inhibitor drugs market size is estimated to reach USD 26.6 billion by 2030, registering a CAGR of 2.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing prevalence of autoimmune diseases, rapid technological advancements, and rise in healthcare expenditure across the globe are some of the major factors expected to drive the growth.

Currently, there are five approved TNF inhibitor drugs in the market- Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab), Simponi/Simponi Aria (golimumab), and Cimzia (certolizumab). Biosimilar versions of Humira, Enbrel, and Remicade have been launched, causing a significant paradigm shift in the market.

The wave of biosimilars pose a significant internal threat to the biologics sale as biosimilars have a comparable efficiency as the original products. The cost-effectiveness of biosimilars makes them an attractive choice in economically sensitive areas. In addition, emerging countries, such as India, China, and South Korea are active participants in the biosimilar market.

Some of the key therapeutic areas involving treatment with TNF inhibitor drugs are rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Although these medicines are mostly used for the treatment of autoimmune diseases, several ongoing studies are investigating the role of TNF inhibitors in the treatment of cancer and other inflammatory conditions.

Some of the key players in the TNF inhibitor space are involved in strategic initiatives, such as mergers and acquisitions and joint ventures for the co-development of products. In addition, patent infringement issues between the manufacturers makes the market dynamics intensely competitive. For instance, AbbVie resolved an issue with Boehringer Ingelheim, regarding Humira's intellectual property (IP) rights. As per the terms of the agreement, Boehringer Ingelheim received a non-exclusive license to Humira's IP in the U.S.- scheduled to begin in July 2023.

Tumor Necrosis Factor Inhibitor Drugs Market Report Highlights:

  • By product, the humira segment dominating the market with the largest revenue share of 40.5% in 2024, due to its proven effectiveness in treating various autoimmune disorders, which fostered strong trust among patients and healthcare providers.
  • In 2024, Rheumatoid arthritis dominated the market and accounted for the largest revenue share of 17.51%, due to its high prevalence globally.
  • The online pharmacy is expected to grow at the highest CAGR over the forecasted period, due to easy access to digital platforms, smooth ordering, in time delivery, and affordable pricing.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Tumor Necrosis Factor Inhibitor Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Tumor Necrosis Factor Inhibitor Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Tumor Necrosis Factor Inhibitor Drugs Market: Product Estimates & Trend Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Humira
    • 4.4.1. Humira Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Enbrel
    • 4.5.1. Enbrel Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Remicade
    • 4.6.1 Remicade Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Simponi/Simponi Aria
    • 4.7.1 Simponi/Simponi Aria Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Cimzia
    • 4.8.1 Cimzia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Biosimilars
    • 4.9.1 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Tumor Necrosis Factor Inhibitor Drugs Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2024 & 2030
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Rheumatoid Arthritis
    • 5.4.1. Rheumatoid Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Psoriasis
    • 5.5.1. Psoriasis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Psoriatic Arthritis
    • 5.6.1. Psoriatic Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Crohn's Disease
    • 5.7.1. Crohn's Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Ulcerative Colitis
  • 5.9. Ulcerative Colitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) Psoriatic Arthritis
  • 5.10. Ankylosing Spondylitis
    • 5.10.1. Ankylosing Spondylitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.11. Juvenile Idiopathic Arthritis
    • 5.11.1. Juvenile Idiopathic Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.12. Hidradenitis suppurativa
    • 5.12.1. Hidradenitis suppurativa Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.13. Others
    • 5.13.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Tumor Necrosis Factor Inhibitor Drugs Market: Sales Channel Estimates & Trend Analysis

  • 6.1. Sales Channel Market Share, 2024 & 2030
  • 6.2. Sales Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacy
    • 6.4.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Speciality Pharmacy
    • 6.5.1. Speciality Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Online Pharmacy
    • 6.6.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Tumor Necrosis Factor Inhibitor Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Denmark Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Sweden Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Norway Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. China Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Japan
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. Japan Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. AbbVie, Inc.
      • 8.5.1.1. Participant's Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Recent Developments/ Strategic Initiatives
    • 8.5.2. Amgen, Inc.
      • 8.5.2.1. Participant's Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Recent Developments/ Strategic Initiatives
    • 8.5.3. Johnson & Johnson Services, Inc.
      • 8.5.3.1. Participant's Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Recent Developments/ Strategic Initiatives
    • 8.5.4. UCB S.A.
      • 8.5.4.1. Participant's Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Recent Developments/ Strategic Initiatives
    • 8.5.5. Pfizer, Inc.
      • 8.5.5.1. Participant's Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Recent Developments/ Strategic Initiatives
    • 8.5.6. Novartis International AG
      • 8.5.6.1. Participant's Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Recent Developments/ Strategic Initiatives
    • 8.5.7. Boehringer Ingelheim Pharmaceuticals, Inc.
      • 8.5.7.1. Participant's Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Recent Developments/ Strategic Initiatives
    • 8.5.8. Merck & Co., Inc.
      • 8.5.8.1. Participant's Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Tumor Necrosis Factor Inhibitor Drugs Market , by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Tumor Necrosis Factor Inhibitor Drugs Market , by Product, 2018 - 2030 (USD Million)
  • Table 5 Global Tumor Necrosis Factor Inhibitor Drugs Market , by Application, 2018 - 2030 (USD Million)
  • Table 6 Global Tumor Necrosis Factor Inhibitor Drugs Market , by Sales Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Tumor Necrosis Factor Inhibitor Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 9 North America Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 10 North America Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 12 U.S. Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 13 U.S. Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 14 Canada Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 15 Canada Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 16 Canada Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 17 Europe Tumor Necrosis Factor Inhibitor Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 18 Europe Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 19 Europe Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 20 Europe Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 21 UK Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 22 UK Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 23 UK Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 24 Germany Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 25 Germany Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 26 Germany Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 27 France Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 28 France Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 29 France Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 30 Italy Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 31 Italy Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 32 Italy Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 33 Spain Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 34 Spain Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 35 Spain Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 37 Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 38 Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 39 Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 40 Japan Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 41 Japan Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 42 Japan Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 43 China Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 44 China Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 45 China Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 46 Latin America Tumor Necrosis Factor Inhibitor Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 47 Latin America Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 48 Latin America Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 49 Latin America Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 50 Brazil Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 51 Brazil Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 52 Brazil Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 53 Argentina Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 54 Argentina Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 55 Argentina Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Tumor Necrosis Factor Inhibitor Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 59 Middle East & Africa Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 60 South Africa Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
  • Table 61 South Africa Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
  • Table 62 South Africa Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Tumor necrosis factor inhibitor drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Tumor Necrosis Factor Inhibitor Drugs Market dynamics
  • Fig. 12 Tumor Necrosis Factor Inhibitor Drugs Market: Porter's five forces analysis
  • Fig. 13 Tumor Necrosis Factor Inhibitor Drugs Market: PESTLE analysis
  • Fig. 14 Tumor Necrosis Factor Inhibitor Drugs Market: Type segment dashboard
  • Fig. 15 Tumor Necrosis Factor Inhibitor Drugs Market: Product market share analysis, 2024 & 2030
  • Fig. 16 Enbrel Market, 2018 - 2030 (USD Million)
  • Fig. 17 Remicade Market, 2018 - 2030 (USD Million)
  • Fig. 18 Simponi/Simponi Aria Market 2018 - 2030 (USD Million)
  • Fig. 19 Cimzia 2018 - 2030 (USD Million)
  • Fig. 20 Biosimilars 2018 - 2030 (USD Million)
  • Fig. 21 Simponi/Simponi Aria market, Cimzia Biosimilars 2018 - 2030 (USD Million)
  • Fig. 22 Tumor Necrosis Factor Inhibitor Drugs Market: Application segment dashboard
  • Fig. 23 Tumor Necrosis Factor Inhibitor Drugs Market: Application market share analysis, 2024 & 2030
  • Fig. 24 Rheumatoid Arthritis Market 2018 - 2030 (USD Million)
  • Fig. 25 Psoriasis Market, 2018 - 2030 (USD Million)
  • Fig. 26 Psoriatic Arthritis Market, 2018 - 2030 (USD Million)
  • Fig. 27 Ankylosing Spondylitis, 2018 - 2030 (USD Million)
  • Fig. 28 Juvenile Idiopathic Arthritis Market, 2018 - 2030 (USD Million)
  • Fig. 29 Hidradenitis suppurativa Market, 2018 - 2030 (USD Million)
  • Fig. 30 Crohn's Disease Market, 2018 - 2030 (USD Million)
  • Fig. 31 Others Market, 2018 - 2030 (USD Million)
  • Fig. 32 Tumor Necrosis Factor Inhibitor Drugs Market: Sales Channel segment dashboard
  • Fig. 33 Tumor Necrosis Factor Inhibitor Drugs Market: Sales Channel market share analysis, 2024 & 2030
  • Fig. 34 Hospital Pharmacy Market, 2018 - 2030 (USD Million)
  • Fig. 35 Speciality Pharmacy Market, 2018 - 2030 (USD Million)
  • Fig. 36 Online Pharmacy Market, 2018 - 2030 (USD Million)
  • Fig. 37 Tumor Necrosis Factor Inhibitor Drugs Market revenue, by Region
  • Fig. 38 Regional Marketplace: Key takeaways
  • Fig. 39 North America Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. country dynamics
  • Fig. 41 U.S. Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 42 Canada country dynamics
  • Fig. 43 Canada Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 44 Europe Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 45 UK country dynamics
  • Fig. 46 UK Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 47 Germany country dynamics
  • Fig. 48 Germany Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 49 France country dynamics
  • Fig. 50 France Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 51 Italy country dynamics
  • Fig. 52 Italy Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 53 Spain country dynamics
  • Fig. 54 Spain Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 55 Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 56 Japan country dynamics
  • Fig. 57 Japan Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 58 China country dynamics
  • Fig. 59 China Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 60 Latin America Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 61 Brazil country dynamics
  • Fig. 62 Brazil Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 63 Argentina country dynamics
  • Fig. 64 Argentina Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 65 MEA Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 66 South Africa country dynamics
  • Fig. 67 South Africa Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 68 Company categorization
  • Fig. 69 Company market position analysis
  • Fig. 70 Strategic framework